Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Egon Pfarr
ResearcherPublications, citations & collaboration network
Egon Pfarr is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 10 works, 95 citations, an h-index of 3 and an i10-index of 2.
10
Works
95
Citations
3
h-index
2
i10-index
IDs:OpenAlex
How has Egon Pfarr's publication output changed over time?
ScholarIQpublication output · 1997–2025
Output grew0% over the shown period — from 1 works in 1997 to 1 in 2025.
1
1
1
1
1
2
1
1
1
199719981999201120182019202020242025
What are the most-cited papers on Egon Pfarr?
ScholarIQmost cited works
Therapeutic Use of the Natriuretic Peptide Ularitide in Acute Renal Failure
Markus Meyer, Egon Pfarr, G. Schirmer, H. J. Überbacher, Klaus Schöpe, Erwin Böhm, Thomas Flüge, P Mentz, P. Scigalla, Wolf‐Georg Forssmann
Renal Failure. 199964 CitationsOPEN ACCESS
Effect of reteplase on hemostasis variables: analysis of fibrin specifity, relation to bleeding complications and coronary patency
Rainer Meierhenrich, J. Carlsson, E. Seifried, Egon Pfarr, A. Smolarz, Karl-Ludwig Neuhaus, Ulrich Tebbe
International Journal of Cardiology. 199823 Citations
EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE
David Fitchett, Silvio E. Inzucchi, Steven Sambevski, Stefan Kaspers, Egon Pfarr, Jyothis T. George, Bernard Zinman
Journal of the American College of Cardiology. 20183 Citations
Thrombolytic therapy in acute massive pulmonary embolism Double bolus reteplase versus conventional alteplase infusion in a randomized controlled trial
U Tebbe, Andreas Graf, W. Kamke, Klaus Bonaventura, R. Zahn, Florian Forycki, Gerhard Kratzsch, Egon Pfarr, Erich Boehm, A. Smolarz
19972 Citations
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial
Anastasia Uster, Nihar R. Desai, Sankar D. Navaneethan, Egon Pfarr, Anna Mazo
Clinical Therapeutics. 20252 CitationsOPEN ACCESS
Related on ScholarIQ
Boehringer Ingelheim (Germany)
Institution
Therapeutic Use of the Natriuretic Peptide Ularitide in Acute Renal Failure
Paper
Effect of reteplase on hemostasis variables: analysis of fibrin specifity, relation to bleeding complications and coronary patency
Paper
EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE
Paper
Thrombolytic therapy in acute massive pulmonary embolism Double bolus reteplase versus conventional alteplase infusion in a randomized controlled trial
Paper
Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial
Paper